Adenosine A
Adenosine A2 Receptor Antagonists
/ pharmacology
Animals
Brain-Computer Interfaces
Calcium Signaling
/ drug effects
Implantable Neurostimulators
Learning
/ drug effects
Mice
Mice, Inbred C57BL
Motor Cortex
/ drug effects
Neurons
/ drug effects
Photometry
/ instrumentation
Purines
/ pharmacology
Receptor, Adenosine A2A
/ metabolism
Volition
/ drug effects
Adenosine A(2A) receptor
Brain-machine interfaces
Neuroprosthetic learning
Population calcium signal
Representation neuroplasticity
Volitional control
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
08
05
2020
revised:
12
07
2020
accepted:
20
07
2020
pubmed:
30
7
2020
medline:
13
8
2021
entrez:
30
7
2020
Statut:
ppublish
Résumé
Volitional control is at the core of brain-machine interfaces (BMI) adaptation and neuroprosthetic-driven learning to restore motor function for disabled patients, but neuroplasticity changes and neuromodulation underlying volitional control of neuroprosthetic learning are largely unexplored. To better study volitional control at annotated neural population, we have developed an operant neuroprosthetic task with closed-loop feedback system by volitional conditioning of population calcium signal in the M1 cortex using fiber photometry recording. Importantly, volitional conditioning of the population calcium signal in M1 neurons did not improve within-session adaptation, but specifically enhanced across-session neuroprosthetic skill learning with reduced time-to-target and the time to complete 50 successful trials. With brain-behavior causality of the neuroprosthetic paradigm, we revealed that proficiency of neuroprosthetic learning by volitional conditioning of calcium signal was associated with the stable representational (plasticity) mapping in M1 neurons with the reduced calcium peak. Furthermore, pharmacological blockade of adenosine A
Identifiants
pubmed: 32726599
pii: S0028-3908(20)30318-X
doi: 10.1016/j.neuropharm.2020.108250
pii:
doi:
Substances chimiques
Adenosine A2 Receptor Antagonists
0
Purines
0
Receptor, Adenosine A2A
0
istradefylline
2GZ0LIK7T4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108250Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.